{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T04:31:43Z","timestamp":1771648303997,"version":"3.50.1"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,2,7]]},"abstract":"<jats:p>This Viewpoint provides a brief history of pharmacy benefit managers (PBMs), describes the ways in which PBMs have acquired influence in the prescription drug distribution system, and suggests possible scenarios surrounding the June 2022 decision by the Federal Trade Commission to launch an investigation into PBM business practices.<\/jats:p>","DOI":"10.1001\/jama.2022.24731","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T16:01:07Z","timestamp":1673280067000},"page":"367","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacy Benefit Managers and the Federal Trade Commission"],"prefix":"10.1001","volume":"329","author":[{"given":"Barak D.","family":"Richman","sequence":"first","affiliation":[{"name":"Law and Business Administration, Duke University School of Law, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli Y.","family":"Adashi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Brown University, Providence, Rhode Island"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"1","key":"jvp220148r4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10754-020-09291-1","article-title":"Do companies in the pharmaceutical supply chain earn excess returns?","volume":"21","author":"Sood","year":"2021","journal-title":"Int J Health Econ Manag"},{"issue":"11","key":"jvp220148r5","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.3409","article-title":"Estimation of the share of net expenditures on insulin captured by US manufacturers, wholesalers, pharmacy benefit managers, pharmacies, and health plans from 2014 to 2018.","volume":"2","author":"Van Nuys","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"2","key":"jvp220148r9","first-page":"487","article-title":"The neglected concern of firm size in pharmaceutical mergers.","volume":"84","author":"Danzon","year":"2022","journal-title":"Antitrust Law J"},{"issue":"22","key":"jvp220148r10","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1001\/jama.2018.4269","article-title":"The evolving pharmaceutical benefits market.","volume":"319","author":"Schulman","year":"2018","journal-title":"JAMA"},{"key":"jvp220148r8"},{"key":"jvp220148r1","unstructured":"FTC launches inquiry into prescription drug middlemen industry. Federal Trade Commission. Published June 7, 2022. Accessed January 4, 2023. https:\/\/www.ftc.gov\/news-events\/news\/press-releases\/2022\/06\/ftc-launches-inquiry-prescription-drug-middlemen-industry"},{"key":"jvp220148r2","unstructured":"Merck settles FTC charges that its acquisition of Medco could cause higher prices and reduced quality for prescription drugs. Federal Trade Commission. Published August 27, 1998. Accessed January 4, 2023. https:\/\/www.ftc.gov\/news-events\/news\/press-releases\/1998\/08\/merck-settles-ftc-charges-its-acquisition-medco-could-cause-higher-prices-reduced-quality"},{"key":"jvp220148r3","unstructured":"Statement of the Federal Trade Commission Concerning the Proposed Acquisition of Medco Health Solutions by Express Scripts, Inc. Federal Trade Commission. FTC File No. 111-0210. Published April 2, 2012. Accessed January 4, 2023. https:\/\/www.ftc.gov\/sites\/default\/files\/documents\/closing_letters\/proposed-acquisition-medco-health-solutions-inc.express-scripts-inc.\/120402expressmedcostatement.pdf"},{"key":"jvp220148r6","unstructured":"Fein? AJ; Drug Channels Institute. The 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. Drug Channels Institute. Published March 2022. Accessed January 4, 2023. https:\/\/drugchannelsinstitute.com\/files\/2022-PharmacyPBM-DCI-Overview.pdf"},{"key":"jvp220148r7","unstructured":"The Use of Medicines in the United States. IQVIA Institute. Published April 2022. Accessed January 4, 2023.  https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/the-use-of-medicines-in-the-us-2022"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2800469\/jama_richman_2023_vp_220148_1674761918.39907.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T16:06:19Z","timestamp":1675785979000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2800469"}},"subtitle":["A Relationship Gone Sour"],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,2,7]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.24731","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,7]]}}}